Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy
about
Sentinel lymph node biopsy alone after neoadjuvant chemotherapy in patients with initial cytology-proven axillary node metastasisEffect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis.A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast CancerEfficacy of vinorelbine-based neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis of randomized controlled trials.Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response.Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients.Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population.Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells.Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
P2860
Q35237199-94AC510D-66F2-4AF0-8FE1-BA5D47104631Q35759050-60BB9769-3976-465D-8646-1B9B0045D8F7Q35862343-6F5C057C-CCAC-4A0B-8279-60582BFA91A2Q35954081-7F96396E-6220-4E79-B19C-85D475243201Q36271681-6F2C23A8-A72A-4F3E-8835-A87B420E7852Q37367411-82D00D5D-BC8A-42A8-91B1-D32C4703E9E2Q37484652-91906009-1BD3-4B1B-8E0E-7A58890A169DQ37705395-C076B464-872B-401A-9CAF-33C21712737CQ38439990-99F51086-B5F2-43EC-B218-DFFAA5D5BAC6Q46542099-6243A31E-E34E-415C-BD07-87A7AB5EB421Q49486164-91A696E3-937B-4AA3-89C7-4F90434F4832Q50047764-5D72902B-66C8-490A-A454-210906546BDBQ54338842-CAAA498B-A1A7-4E35-918B-3644249CE8B9
P2860
Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Impact of immunohistochemistry ...... owing neoadjuvant chemotherapy
@ast
Impact of immunohistochemistry ...... owing neoadjuvant chemotherapy
@en
type
label
Impact of immunohistochemistry ...... owing neoadjuvant chemotherapy
@ast
Impact of immunohistochemistry ...... owing neoadjuvant chemotherapy
@en
prefLabel
Impact of immunohistochemistry ...... owing neoadjuvant chemotherapy
@ast
Impact of immunohistochemistry ...... owing neoadjuvant chemotherapy
@en
P2093
P2860
P1476
Impact of immunohistochemistry ...... owing neoadjuvant chemotherapy
@en
P2093
Byung Ho Son
Changhoon Yoo
Gyungyub Gong
Hak-Hee Kim
Hee Jung Shin
Jin-Hee Ahn
Kyung Hae Jung
Sei Hyun Ahn
Sung-Bae Kim
P2860
P304
P356
10.4048/JBC.2012.15.2.203
P577
2012-06-28T00:00:00Z